Abstract
BackgroundInhibition of the interleukin IL6 receptor pathway by tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). TCZ reduces atherosclerosis markers and improves endothelial function. In peripheral blood, TCZ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have